Maternal exposure to angiotensin converting enzyme inhibitors in the first trimester and risk of malformations in offspring: a retrospective cohort study

Research

BMJ 2011; 343 doi: https://doi.org/10.1136/bmj.d5931 (Published 18 October 2011) Cite this as: BMJ 2011;343:d5931

Data supplement

Birth prevalence and risk factors of neural tube defects in Ethiopia: a systematic review and meta-analysis
- Abstract
- Fulltext
- PDF
What is the evidence for using labetalol as a first-line treatment option for hypertension in pregnancy?
- Abstract
- Fulltext
- PDF
Maternal Antihypertensive Medication Use and Congenital Heart Defects: Updated Results From the National Birth Defects Prevention Study
- Abstract
- Fulltext
- PDF
Management of a new pregnancy in a woman with chronic hypertension
- Abstract
- Fulltext
- PDF
Preeclampsia: Updates in Pathogenesis, Definitions, and Guidelines
- Abstract
- Fulltext
- PDF
Chronic hypertension and pregnancy outcomes: systematic review and meta-analysis
- Abstract
- Fulltext
- PDF
Chronic Hypertension in Pregnancy
- Abstract
- Fulltext
- PDF
The Risk of Congenital Malformations Associated With Exposure to {beta}-Blockers Early in Pregnancy: A Meta-Analysis
- Abstract
- Fulltext
- PDF
Patterns of Outpatient Antihypertensive Medication Use During Pregnancy in a Medicaid Population * Novelty and Significance
- Abstract
- Fulltext
- PDF
Angiotensin-Converting-Enzyme Inhibitors During Early Pregnancy Aren't Significantly Associated with Fetal Malformations
- Abstract
- Fulltext
- PDF
Fetal risk from ACE inhibitors in the first trimester
- Abstract
- Fulltext
- PDF